Advanced search
Publication Cover
Future Oncology Volume 16, 2020 - Issue 15
Submit an article Journal homepage
4,584
Views
11
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1

Grzegorz S Nowakowski1 Division of Hematology,Mayo Clinic,Rochester,MN,USAView further author information
,
Jun Zhu2 Peking University Cancer Hospital & Institute,Beijing,PR ChinaCorrespondence[email protected]
View further author information
,
Qingyuan Zhang3 Harbin Medical University Cancer Hospital,Harbin,PR ChinaView further author information
,
Joshua Brody4 Icahn School of Medicine at Mount Sinai,New York,NY,USAView further author information
,
Xiuhua Sun5 The Second Hospital of Dalian Medical University,Dalian,PR ChinaView further author information
,
Joseph Maly6 Norton Cancer Institute,Louisville,KY,USAView further author information
,
Yuqin Song2 Peking University Cancer Hospital & Institute,Beijing,PR ChinaView further author information
,
Syed Rizvi7 University of Texas Southwestern Medical Center,Dallas,TX,USAView further author information
,
Yongping Song8 Affliliated Cancer Hospital of Zhengzhou University,Zhengzhou,PR ChinaView further author information
,
Frederick Lansigan9 Dartmouth-Hitchcock Medical Center,Lebanon,NHView further author information
,
Hongmei Jing10 Peking University Third Hospital,Beijing,PR ChinaView further author information
,
Junning Cao11 Fudan University Shanghai Cancer Center,Shanghai,PR ChinaView further author information
,
Jennifer K Lue12 Columbia University Medical Center, New York,NY,USAView further author information
,
Wen Luo13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
,
Lei Zhang13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
,
Ling Li13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
,
Isabel Han13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
,
Joan Sun13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
,
Manoj Jivani13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
,
Young Liu13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
,
Thomas Heineman13 Denovo Biopharma LLC,San Diego,CA,USAView further author information
&
Stephen D Smith14 University of Washington/Fred Hutchinson Cancer Center,Seattle,WA,USAView further author information
 show all
Pages 991-999 | Received 28 Feb 2020, Accepted 24 Mar 2020, Published online: 06 Apr 2020

References

  • WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. SwerdlowSH, CampoE, HarrisNL, PileriS, SteinH, ElaineS. ( Eds). IARC Press, Lyon, France (2008).
  • Møller MB , PedersenNT, ChristensenBE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation – a population-based study of 1575 cases. Br. J. Haematol.124, 151–159 (2004).
  • Intragumtornchai T , BunworasateU, WudhikarnKet al. Non-Hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features and survival from Thailand. Hematol. Oncol.36(1), 28–36 (2018).
  • Nowakowski G , ChiapellaA, WitzigTet al. ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncology12(13), 1553–1563 (2016).
  • Roschewski M , DunleavyK, WilsonWH. Diffuse large B-cell lymphoma: molecular targeted therapy. Int. J. Hematol.96(5), 552–561 (2012).
  • Sehn L , GascoyneR. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood125, 22–32 (2015).
  • Zhou Z , SehnLH, RademakerAWet al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood123, 837–842 (2014).
  • Chiapella A , CastellinoA, VitoloU. State-of-the-art therapy for advanced-stage diffuse large B-cell lymphoma. Hematol. Oncol. Clin. North Am.30, 1147–1162 (2016).
  • Maurer MJ , GhesquièresH, JaisJPet al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol.32(10), 1066–1073 (2014).
  • Robertson M , KahlBS, VoseJMet al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol.25(13), 1741–1746 (2007).
  • Abramson J , ShippM. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood106, 1164–1174 (2005).
  • Lee KW , KimSG, KimHPet al. Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res.68(6), 1916–1926 (2008).
  • Flowers CR , SihnaR, VoseJM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J. Clin.60(6), 393–408 (2010).
  • Shipp MA , RossKN, TamayoPet al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat. Med.8, 68–74 (2002).
  • Carducci MA , MusibL, KiesMSet al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol.24(25), 4092–4099 (2006).
  • Kreisl T , KotliarovaS, ButmanJet al. A Phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol.12(2), 181–189 (2010).
  • Crump M , LeppaS, HabermannTet al. Randomized, double-blind, Phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J. Clin. Oncol.34(21), 2484–2492 (2016).
  • Camicia R , WinklerHC, HassaPO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol. Cancer14, 207 (2015).
  • Bourhill T , NarendranA, JohnstonR Net al. Enzastaurin: a lesson in drug development. Crit. Rev. Oncol. Hematol.112, 72–79 (2017).
  • Hainsworth JD , ArrowsmithER, FayadLet al. A randomized, Phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate or high-risk diffuse large B-cell lymphoma. Leuk. Lymphoma57(1), 216–218 (2016).
  • Li X , FangX, LinTet al. A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma. Oncotarget7(14), 18585–18593 (2016).
  • Denovo Biomarker Platform Patent, Inc.: WO 2012/106267 (2012).
  • Luo W , SunH, ShazerRet al. Improved survival with enzastaurin treatment in diffuse large B-cell lymphoma (DLBCL) patients with the novel genetic biomarker, DGM1. Presented at:American Society of Hematology. San Diego, CA, USA, 1–4 December 2018.
  • Chen JQ , BaoY, LeeJet al. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann. Oncol.24(10), 2534–254 (2013).
  • Wu L , WangY, LiuYet al. A central role for TRPS1 in the control of cell cycle and cancer development. Oncotarget5, 7677–7690 (2014).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.